Cargando…

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification

BACKGROUND: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and immune activation. METHODS: Thai patients with F...

Descripción completa

Detalles Bibliográficos
Autores principales: Ananworanich, Jintanat, Chomont, Nicolas, Fletcher, James LK, Pinyakorn, Suteeraporn, Schuetz, Alexandra, Sereti, Irini, Rerknimitr, Rungsun, Dewar, Robin, Kroon, Eugene, Vandergeeten, Claire, Trichavaroj, Rapee, Chomchey, Nitiya, Chalermchai, Thep, Michael, Nelson L, Kim, Jerome H, Phanuphak, Praphan, Phanuphak, Nittaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729387/
https://www.ncbi.nlm.nih.gov/pubmed/26835516
_version_ 1782412247661805568
author Ananworanich, Jintanat
Chomont, Nicolas
Fletcher, James LK
Pinyakorn, Suteeraporn
Schuetz, Alexandra
Sereti, Irini
Rerknimitr, Rungsun
Dewar, Robin
Kroon, Eugene
Vandergeeten, Claire
Trichavaroj, Rapee
Chomchey, Nitiya
Chalermchai, Thep
Michael, Nelson L
Kim, Jerome H
Phanuphak, Praphan
Phanuphak, Nittaya
author_facet Ananworanich, Jintanat
Chomont, Nicolas
Fletcher, James LK
Pinyakorn, Suteeraporn
Schuetz, Alexandra
Sereti, Irini
Rerknimitr, Rungsun
Dewar, Robin
Kroon, Eugene
Vandergeeten, Claire
Trichavaroj, Rapee
Chomchey, Nitiya
Chalermchai, Thep
Michael, Nelson L
Kim, Jerome H
Phanuphak, Praphan
Phanuphak, Nittaya
author_sort Ananworanich, Jintanat
collection PubMed
description BACKGROUND: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and immune activation. METHODS: Thai patients with Fiebig I–IV AHI were prospectively enrolled and offered treatment. They were randomised 1 : 1 to HAART (tenofovir/emtricitabine/efavirenz, n=31) or megaHAART, a standard regimen intensified by raltegravir/maraviroc (n=31), during the first 24 weeks of therapy. Participants were monitored at weeks 0, 2, 4, 8 and 12, then every 12 weeks. Frequencies of peripheral blood mononuclear cells (PBMCs) carrying HIV DNA (total, integrated and 2-LTR episomes), plasma C-reactive protein (CRP) concentrations, and frequencies of activated T cells were measured. Flexible sigmoidoscopy was performed in willing participants (n=25) at baseline, weeks 24 and 96, and proviral DNA and RNA were determined. RESULTS: Baseline characteristics were similar in the HAART and megaHAART arms. Median age was 28 years and 95% were men. Median CD4 cell count was 388 cells/mm(3). HIV RNA was 5.6 log(10) copies/mL. HIV RNA declined more rapidly in the first 4 weeks with megaHAART (median –3.3 log(10)) than HAART (–2.6 log(10)). Time to achieve HIV RNA <50 copies/mL was shorter with megaHAART (median 55 days) than HAART (83 days, P=0.04). Viral suppression rates after week 12 did not differ between arms, and overall, 97% achieved suppression by week 48. The frequency of cells harbouring total HIV DNA was similarly low after 96 weeks in both treatment arms (median of 7 and 4 copies/10(6) PBMCs in the megaHAART and HAART arms, respectively, P=0.41). At weeks 2 and 12, frequency of cells carrying 2-LTR circles were significantly higher with megaHAART (P=0.03). In the sigmoid colon, total HIV DNA and HIV RNA declined after treatment, with no differences between arms. The frequencies of cells with 2-LTR circles were also higher in the sigmoid colon at week 24 with megaHAART. Plasma levels of CRP and frequencies of CD4+ and CD8+ T cells expressing CD38 and HLA-DR or Ki67 were similar between arms. CONCLUSIONS: Intensification of standard HAART with raltegravir and maraviroc was not associated with either statistically significant reductions of markers of HIV reservoir size in blood and sigmoid colon or markers of immune activation in blood.
format Online
Article
Text
id pubmed-4729387
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Mediscript Ltd
record_format MEDLINE/PubMed
spelling pubmed-47293872016-01-27 Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification Ananworanich, Jintanat Chomont, Nicolas Fletcher, James LK Pinyakorn, Suteeraporn Schuetz, Alexandra Sereti, Irini Rerknimitr, Rungsun Dewar, Robin Kroon, Eugene Vandergeeten, Claire Trichavaroj, Rapee Chomchey, Nitiya Chalermchai, Thep Michael, Nelson L Kim, Jerome H Phanuphak, Praphan Phanuphak, Nittaya J Virus Erad Original Research BACKGROUND: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and immune activation. METHODS: Thai patients with Fiebig I–IV AHI were prospectively enrolled and offered treatment. They were randomised 1 : 1 to HAART (tenofovir/emtricitabine/efavirenz, n=31) or megaHAART, a standard regimen intensified by raltegravir/maraviroc (n=31), during the first 24 weeks of therapy. Participants were monitored at weeks 0, 2, 4, 8 and 12, then every 12 weeks. Frequencies of peripheral blood mononuclear cells (PBMCs) carrying HIV DNA (total, integrated and 2-LTR episomes), plasma C-reactive protein (CRP) concentrations, and frequencies of activated T cells were measured. Flexible sigmoidoscopy was performed in willing participants (n=25) at baseline, weeks 24 and 96, and proviral DNA and RNA were determined. RESULTS: Baseline characteristics were similar in the HAART and megaHAART arms. Median age was 28 years and 95% were men. Median CD4 cell count was 388 cells/mm(3). HIV RNA was 5.6 log(10) copies/mL. HIV RNA declined more rapidly in the first 4 weeks with megaHAART (median –3.3 log(10)) than HAART (–2.6 log(10)). Time to achieve HIV RNA <50 copies/mL was shorter with megaHAART (median 55 days) than HAART (83 days, P=0.04). Viral suppression rates after week 12 did not differ between arms, and overall, 97% achieved suppression by week 48. The frequency of cells harbouring total HIV DNA was similarly low after 96 weeks in both treatment arms (median of 7 and 4 copies/10(6) PBMCs in the megaHAART and HAART arms, respectively, P=0.41). At weeks 2 and 12, frequency of cells carrying 2-LTR circles were significantly higher with megaHAART (P=0.03). In the sigmoid colon, total HIV DNA and HIV RNA declined after treatment, with no differences between arms. The frequencies of cells with 2-LTR circles were also higher in the sigmoid colon at week 24 with megaHAART. Plasma levels of CRP and frequencies of CD4+ and CD8+ T cells expressing CD38 and HLA-DR or Ki67 were similar between arms. CONCLUSIONS: Intensification of standard HAART with raltegravir and maraviroc was not associated with either statistically significant reductions of markers of HIV reservoir size in blood and sigmoid colon or markers of immune activation in blood. Mediscript Ltd 2015-04-01 /pmc/articles/PMC4729387/ /pubmed/26835516 Text en © 2015 The Authors. Journal of Virus Eradication published by Mediscript Ltd http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article published under the terms of a Creative Commons License.
spellingShingle Original Research
Ananworanich, Jintanat
Chomont, Nicolas
Fletcher, James LK
Pinyakorn, Suteeraporn
Schuetz, Alexandra
Sereti, Irini
Rerknimitr, Rungsun
Dewar, Robin
Kroon, Eugene
Vandergeeten, Claire
Trichavaroj, Rapee
Chomchey, Nitiya
Chalermchai, Thep
Michael, Nelson L
Kim, Jerome H
Phanuphak, Praphan
Phanuphak, Nittaya
Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
title Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
title_full Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
title_fullStr Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
title_full_unstemmed Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
title_short Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
title_sort markers of hiv reservoir size and immune activation after treatment in acute hiv infection with and without raltegravir and maraviroc intensification
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729387/
https://www.ncbi.nlm.nih.gov/pubmed/26835516
work_keys_str_mv AT ananworanichjintanat markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT chomontnicolas markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT fletcherjameslk markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT pinyakornsuteeraporn markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT schuetzalexandra markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT seretiirini markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT rerknimitrrungsun markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT dewarrobin markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT krooneugene markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT vandergeetenclaire markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT trichavarojrapee markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT chomcheynitiya markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT chalermchaithep markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT michaelnelsonl markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT kimjeromeh markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT phanuphakpraphan markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification
AT phanuphaknittaya markersofhivreservoirsizeandimmuneactivationaftertreatmentinacutehivinfectionwithandwithoutraltegravirandmaravirocintensification